Medicinal Chemistry Journal of Medicinal Chemistry

KRAS G12D inhibitor INCB161734: how the clinical candidate was optimized

  • Optimization started from an earlier orally bioavailable KRAS G12D tool compound, with the explicit goal of lowering the predicted human dose by tuning potency and pharmacokinetics together.
  • Metabolic soft-spot analysis guided the design of low-clearance analogs; molecular size and Fsp3 were held in check to improve permeability and crystalline solubility.
  • The resulting candidate shows strong oral exposure, antiproliferative activity in xenograft models and selectivity over wild-type K/H/NRAS; it is now in patient trials.
Points Based on the abstract

Selectivity over wild-type RAS is the headline, but its origin is unclear: engagement of the mutant aspartate, as in other non-covalent G12D series, or something distinct. Keeping size and Fsp3 down while pushing clearance lower is a genuinely hard balance in this class. Cellular selectivity against G12V and G12C backgrounds would show how far the mutant preference extends.